The first International Symposium on Phaeochromocytoma in 2005 was followed by considerable progress in the field, largely owing to the many collaborations and networks stimulated by that and subsequent meetings. The rich hereditary background of phaeochromocytomas has since provided for strong interdisciplinary links of genetics with personalized diagnostics, imaging and therapeutic interventions.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dahia, P. L. M. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat. Rev. Cancer 14, 108–119 (2014).
Eisenhofer, G., Klink, B., Richter, S., Lenders, J. W. M. & Robledo, M. Metabologenomics of phaeochromocytoma and paraganglioma: an integrated approach for personalised biochemical and genetic testing. Clin. Biochem. Rev. 38, 69–100 (2017).
Taïeb, D., Jha, A., Treglia, G. & Pacak, K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr. Relat. Cancer 26, R627–R652 (2019).
Nölting, S., Grossman, A. & Pacak, K. Metastatic phaeochromocytoma: spinning towards more promising treatment options. Exp. Clin. Endocrinol. Diabetes 127, 117–128 (2019).
Pacak, K. et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat. Clin. Pract. Endocrinol. Metab. 3, 92–102 (2007).
Fishbein, L. et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31, 181–193 (2017).
Crona, J., Taïeb, D. & Pacak, K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr. Rev. 38, 489–515 (2017).
Job, S. et al. Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clin. Cancer Res. 25, 760–770 (2019).
Taïeb, D. et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 46, 2112–2137 (2019).
Lenders, J. W. M. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014).
The authors declare no competing interests.
International Collaboration on Cancer Reporting: www.iccr-cancer.org/datasets
About this article
Cite this article
Pacak, K., Eisenhofer, G. & Tischler, A.S. Phaeochromocytoma — advances through science, collaboration and spreading the word. Nat Rev Endocrinol 16, 621–622 (2020). https://doi.org/10.1038/s41574-020-00413-w
Nature Reviews Endocrinology (2020)